Showing 6071-6080 of 9536 results for "".
- Patient Savings Program Available for Mylan's Doxycycline Hyclatehttps://practicaldermatology.com/news/20130925-patient_savings_program_available_for_mylans_doxycycline_hyclate/2459450/Patients who are prescribed Mylan's bioequivalent alternative to Doryx (doxycycline hyclate delayed-release tablets) USP for severe acne may be eligible for an instant savings program. Patients who take their prescriptions to participating pharmacies will receive an automatic co-pay reduction at the
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 v
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Se
- Roche's Erivedge OK'd in Canadahttps://practicaldermatology.com/news/20130827-roches_erivedge_okd_in_canada/2459474/Erivedge (vismodegib) was recently approved in Canada for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
- Speedier Drug Approvals Not Tied to Increased Warnings or Health Riskshttps://practicaldermatology.com/news/20130815-speedier_drug_approvals_not_tied_to_increased_warnings_or_health_risks/2459478/Faster drug approvals in the US and Canada are not linked to increases in the number of serious drug safety warnings issued by regulators, nor to actual evidence of health risks, according to new research. Investigators compared data about the number of drug safety warnings issued by regulators in t
- Iagnosis, Inc., Launches Mobile App for DermatologistOnCall®https://practicaldermatology.com/news/20130815-iagnosis_inc_launches_mobile_app_for_dermatologistoncall/2459479/A new app for an online dermatology platform has recently launched from Iagnosis, Inc. The DermatologistOnCall® app, based on the website www.dermatologistoncall.com, enables to create an account and submit photographs and descriptions of their condition. Patients then receive a response from a boar
- AARS Hosting Acne and Rosacea Bootcamp September 6-8, 2013https://practicaldermatology.com/news/20130809-aars_hosting_acne_and_rosacea_bootcamp_september_6-8_2013/2459481/The American Acne and Rosacea Society (AARS) is hosting the Acne and Rosacea Bootcamp, a two-day CME event open to all medical health professionals involved in the management of acne and rosacea. The program will be held September 6-8, 2013 at the Hyatt Chicago Magnificent Mile. This event will p
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m